Nalu Medical has announced the publication of 24-month results from its COMFORT randomized controlled trial evaluating the Nalu Neurostimulation System for chronic intractable pain. The data, now published in Chronic Pain & Management, show that the device achieved durable efficacy across pain relief, functional improvement, and patient satisfaction, with over 85 percent of patients classified as responders and nearly three in ten as high responders after two years of follow-up.

The results place the Nalu Peripheral Nerve Stimulation (PNS) platform in a stronger competitive position in the neuromodulation market, particularly among patients with localized nerve pain who have not responded to conventional treatment modalities. Beyond efficacy, the trial also reinforces the commercial narrative around Nalu’s battery-free, wearable-powered system, which continues to challenge the legacy design norms of fully implanted stimulators.

What the 24-month data confirms about Nalu’s device design and target strategy

The most immediate takeaway from the COMFORT trial extension is not just the sustained efficacy but the consistency of outcomes across anatomical locations. Unlike some neuromodulation systems that are optimized for specific nerve distributions or centralized pain targets, Nalu Medical’s system demonstrated reliable results regardless of the site of stimulation. That cross-target reliability is emerging as a key differentiator, especially as clinicians push for device flexibility in complex pain presentations.

At the 24-month mark, over 85 percent of patients in both the active and crossover arms met the ≥50 percent pain reduction threshold. Nearly 30 percent were high responders, reporting pain relief of 80 percent or greater. In addition to pain metrics, the trial also tracked functional and quality of life improvements. Over 70 percent of subjects reported clinically significant functional gains, and a similar proportion noted better quality of life. Importantly, 96 percent of patients remained satisfied with the therapy—a high mark for any implantable system.

These outcomes align with earlier data points from the 3-, 6-, and 12-month interim analyses but carry greater weight due to the long-term horizon. Two-year follow-up remains the gold standard for durability in neuromodulation trials, particularly when payers, clinicians, and regulators seek reassurance that early response rates are not short-lived or skewed by the placebo effect.

Why clinical durability is now central to PNS market adoption and coverage decisions

The broader relevance of the COMFORT data lies in its timing. Peripheral nerve stimulation continues to expand its footprint beyond niche indications, but coverage decisions remain fragmented across payers. In that context, trials that demonstrate both safety and durable efficacy across anatomies are especially valuable. These are the types of results that can support expanded reimbursement, particularly in cases where off-label or anatomically diverse uses are involved.

Industry observers note that a 24-month endpoint with robust responder rates and minimal adverse events is not just clinically reassuring but also a strategic enabler in payer negotiations. For providers, a high satisfaction rate coupled with functional gains improves the therapy’s positioning under value-based care metrics. The data could also strengthen Nalu Medical’s case for broader inclusion in multidisciplinary pain management programs.

From a regulatory perspective, the device is already FDA-cleared for both spinal cord stimulation (SCS) and PNS. However, the COMFORT data primarily speaks to the PNS use case, which remains less saturated than the SCS segment and arguably more dynamic in terms of device innovation.

What distinguishes Nalu’s system from larger IPG competitors

Nalu Medical’s key innovation lies not only in therapy outcomes but also in its form factor and system architecture. The device uses a miniaturized, battery-free implantable pulse generator (IPG) powered externally by a wearable “Therapy Disc.” This configuration removes the need for large surgical pockets, reduces hardware fatigue, and potentially lowers long-term maintenance burden.

Unlike traditional IPG systems that require periodic replacement surgeries due to battery depletion, Nalu’s approach separates the power source from the implant entirely. This could provide long-term cost savings and reduce patient dropout due to surgical fatigue or fear of hardware complications.

Clinicians tracking the PNS space believe this architecture may also improve adoption among younger or more active patients, who are often concerned about device bulk and physical limitations. Moreover, because the system is controlled via a smartphone app, it supports remote programming flexibility and software upgrades without surgical intervention.

The trade-off, of course, is that patients must wear an external component daily to power the system. While satisfaction data from the COMFORT trial suggests this is not a significant deterrent, real-world adherence beyond two years will remain a focus area for clinicians and device analysts alike.

What could still slow adoption despite the trial’s strengths

While the COMFORT data helps cement Nalu’s credibility in long-term pain management, several risks remain. First, adoption may be constrained by clinical inertia and payer conservatism. Despite regulatory clearance, many pain specialists remain entrenched in legacy SCS pathways, especially in systems where they already have training or procurement relationships.

Second, the COMFORT trial’s strong outcomes were achieved in a controlled study environment. Real-world variability—including anatomical targeting complexity, trial-to-permanent conversion rates, and therapy adherence—could affect performance once scaled. Although the high satisfaction rate is promising, industry observers caution that real-world dropout rates tend to rise after initial implantation, especially in systems that rely on consistent user interaction with external components.

Finally, manufacturing scalability and support infrastructure could become limiting factors if demand increases. Nalu’s technology is sophisticated and differentiated, but commercial success will depend on ensuring broad device availability, streamlined surgical training, and payer alignment across geographies.

What the COMFORT results signal for investors and competitors in neuromodulation

From an industry vantage point, the COMFORT data makes Nalu Medical harder to ignore as a mid-stage disruptor in PNS. The company is still private, but its technology platform is now backed by long-term, peer-reviewed clinical validation. For potential acquirers or investors, this kind of differentiated, modular system with FDA clearance and strong satisfaction data could represent a strategic bolt-on asset, especially for larger players looking to refresh aging portfolios in the neurostimulation segment.

Competitively, the data creates pressure on other PNS and hybrid systems to demonstrate equivalent durability. The bar for clinical relevance in nerve stimulation is now moving past six- and twelve-month endpoints into multi-year follow-up. Device manufacturers without long-horizon outcomes data may find themselves disadvantaged in both payer negotiations and academic credibility.

Clinicians, meanwhile, will be watching for real-world performance metrics, trial conversion rates, and any updates to guidelines or payer bulletins that could validate broader use of Nalu’s platform.

What shifts now that 24-month data is in

The publication of 24-month results from the COMFORT randomized controlled trial marks a pivotal milestone in the validation of the Nalu Neurostimulation System for chronic peripheral nerve pain. By demonstrating sustained efficacy across a diverse patient population, Nalu Medical strengthens its clinical credibility and commercial positioning in a fragmented but growing PNS market. The company’s battery-free, wearable-powered system offers meaningful differentiation, especially in a category long dominated by bulky, battery-reliant IPGs.

While questions remain around real-world adherence, manufacturing scale, and market penetration, the COMFORT data gives both clinicians and payers new confidence in the therapy’s durability. For competitors, the trial raises the bar on what long-term success in neuromodulation must look like.

  chronic pain, COMFORT Trial, FDA Cleared Devices, Implantable Pulse Generator, Nalu Medical, Nalu Neurostimulation System, neuromodulation, Peripheral Nerve Stimulation, Wearable Medical Devices